Evotec to Gain $100 Million from Tubulis Sale

Evotec SE has announced an expected receipt of approximately $100 million following the sale of Tubulis GmbH to Gilead Sciences. As part of its 3.14% equity stake in Tubulis, Evotec could gain an additional $58 million contingent upon achieving certain milestones. This transaction aligns with Evotec's strategy to monetize its investment portfolio, marking the fourth successful monetization of assets.

Evotec initially invested in Tubulis during a Series B financing round in 2022. Tubulis is actively developing antibody-drug conjugates, with two programs currently in clinical trials targeting high-need solid tumors. The transaction is anticipated to close in the second quarter of 2026, subject to customary conditions.